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Abstract: 
Manganese (Mn) is an essential mineral that is found at low levels in food, water, and the air. Under certain 
high-dose exposure conditions, elevations in tissue manganese levels can occur. Excessive manganese 
accumulation can result in adverse neurological, reproductive, and respiratory effects in both laboratory animals 
and humans. In humans, manganese-induced neurotoxicity (manganism) is the overriding concern since 
affected individuals develop a motor dysfunction syndrome that is recognized as a form of parkinsonism. This 
review primarily focuses on the essentiality and toxicity of manganese and considers contemporary studies 
evaluating manganese dosimetry and its transport across the blood—brain barrier, and its distribution within the 
central nervous system (CNS). These studies have dramatically improved our understanding of the health risks 
posed by manganese by determining exposure conditions that lead to increased concentrations of this metal 
within the CNS and other target organs. Most individuals are exposed to manganese by the oral and inhalation 
routes of exposure; however, parenteral injection and other routes of exposure are important. Interactions 
between manganese and iron and other divalent elements occur and impact the toxicokinetics of manganese, 
especially following oral exposure. The oxidation state and solubility of manganese also influence the 
absorption, distribution, metabolism, and elimination of manganese. Manganese disposition is influenced by the 
route of exposure. Rodent inhalation studies have shown that manganese deposited within the nose can undergo 
direct transport to the brain along the olfactory nerve. Species differences in manganese toxicokinetics and 
response are recognized with nonhuman primates replicating CNS effects observed in humans while rodents do 
not. Potentially susceptible populations, such as fetuses, neonates, individuals with compromised hepatic 
function, individuals with suboptimal manganese or iron intake, and those with other medical states (e.g., pre-
parkinsonian state, aging), may have altered manganese metabolism and could be at greater risk for manganese 
toxicity. 
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Article: 
I NTRODUCTION 
As with other essential minerals, there is a dichotomy to the response of the body to manganese. Adverse health 
effects can occur when body stores of manganese are either too low (deficiency) or too high (toxicity). 
Manganese deficiency has been recognized in experimental animals and is associated with impaired growth, 
skeletal defects, reduced reproductive function, and abnormal glucose tolerance, as well as altered lipid and 
carbohydrate metabolism.
1,2
 Because of its widespread presence in human diets, manganese deficiency is 
generally not recognized in humans. Under certain high-dose exposure conditions manganese may accumulate 
within the human body, and it can induce adverse neurological, reproductive, and respiratory effects. 
Manganese neurotoxicity is especially pernicious and in chronic states is characterized by damage to 
dopaminergic neurons within brain regions that control muscle movement.
3-5
 
 
For most individuals, the primary source of manganese is the diet. Only a small percentage of the ingested 
manganese is absorbed and even less is ultimately delivered to the brain. Brain delivery of manganese is 
regulated by a number of physiological systems that includes the normal function of the gastrointestinal tract, 
hepatobiliary system, transferrin and other blood trans-port proteins, and the blood—brain barrier. A hallmark 
feature of manganese neurotoxicity is the development of increased brain manganese concentrations. 
Abnormally high brain manganese delivery can occur when these regulatory systems are partially bypassed as 
in the case of inhalation
3,6,7 
or when these control systems are overwhelmed due to the ingestion of extremely 
high levels of manganese in drinking water.
8,9
 Enhanced brain manganese delivery may also occur when 
hepatobiliary or other disease states compromise normal manganese homeostasis. 
 
There is increased interest within the scientific community on the neurotoxicity of manganese. Manganese is 
ubiquitous in the atmosphere, and it is associated with numerous industrial processes.
10
 Other factors that have 
fostered this attention include the increasing worldwide use of methylcyclopentadienyl manganese tricarbonyl 
(MMT) as a gasoline fuel additive and an enhanced awareness that manganese may play a role in hepatic 
encephalopathy and other neurologic diseases. Another recent development is the application of modern brain 
imaging techniques to the evaluation of brain manganese deposition. These imaging studies are likely to yield 
important new insights into manganese-induced neurotoxicity. Manganese exposure is likewise the interest of 
numerous governmental regulatory agencies. Manganese is listed as an air toxic by the U.S. Environmental 
Protection Agency (U.S. EPA). The U.S. EPA (see http://www.epa.gov/iris/subst/0373.htm) has established an 
inhalation reference concentration for respirable manganese (0.05 μg Mn/m
3
). Environmental monitoring 
studies have shown that human exposures are often below this leve1.
11
 
 
This review focuses on the dosimetry of manganese and provides information about exposure conditions that 
lead to increased concentrations of the metal within the central nervous system (CNS) and other target sites. 
This review is not meant as an exhaustive listing of the manganese literature; rather, it is intended to provide a 
useful synopsis of contemporary studies from which the reader may progress to other research citations as 
desired. Specific emphasis is directed at recent published literature on manganese toxicokinetics. Issues 
specifically addressed in this review include the following: (a) the essentiality and toxicity of manganese; (b) 
the absorption, distribution, metabolism, and elimination of manganese in the general population and potentially 
susceptible subpopulations; and (c) potential biomarkers of manganese exposure. Neurological effects induced 
by manganese are a special focus throughout this article. 
 
MANGANESE ESSENTIALITY AND TOXICITY 
Manganese Essentiality 
Manganese is an essential trace metal that is found in all tissues and is required for normal amino acid, lipid, 
protein, and carbohydrate metabolism. Manganese-dependent enzyme families include oxidoreductases, 
transferases, hydrolases, lyases, isomerases,. and ligases. Manganese metalloenzymes include arginase, 
glutamine synthetase, phosphoenolpyruvate decarboxylase, and manganese superoxide dismutase. Manganese is 
involved in the function of numerous organ systems, and it is needed for normal immune function, regulation of 
blood sugars and cellular energy, reproduction, digestion, bone growth, and it aids in defense mechanisms 
against free radicals. Manganese in concert with vitamin K supports the clotting of the blood. 
 
No formal Recommended Dietary Allowance (RDA) for manganese has been established, but the U.S. National 
Research Council has established an estimated safe and adequate dietary intake (ESADDI) of 2-5 mg/day for 
adults.
13
 Factors that influence the daily manganese requirement have been recently reviewed.
14
 The adequate 
intake for manganese for adult men and women is 2.3 and 1.8 mg/day, respectively.
14
 Finley et al.
15
 reported 
that men absorbed significantly less manganese than women from the gastrointestinal tract. It has been 
postulated that this decrease in gastrointestinal manganese absorption is related to iron status and the lower 
serum ferritin concentrations found in men.
14,15 
Lactation and gestation are thought to increase the manganese 
requirement.
14 
Developmental life stage can also influence dietary manganese requirements. Adequate intakes 
for newborn ( <6 months of age) infants are approximately 3 μg/day, while intakes increase to 600 μg/day by 7 
to 12 months of age.
14
 Children 1-3 and 4-8 years of age have adequate daily manganese intakes of 
approximately 1.2 and 1.5 mg/day. 
 
Manganese Deficiency 
Manganese deficiency can result in a host of adverse health effects, including impaired growth, poor bone 
formation and skeletal defects, reduced fertility and birth defects, abnormal glucose tolerance, and altered lipid 
and carbohydrate metabolism.
1,2
 Al-though manganese deficiency has been observed in animals, to our 
knowledge, frank manganese deficiency has not been clinically recognized in humans. Some clinical signs and 
symptoms have been observed in human subjects placed on manganese deficient diets. Young men placed on 
manganese-depleted diet developed an erythematous rash on their torsos.
16
 Penland and Johnson reported that 
young women consuming a diet containing only 1 mg Mn/day developed altered mood and increased pain 
during the premenstrual phase of their estrous cycle.
17
 
 
Manganese intake by many individuals remains below the recommended dietary reference intake level of 1.8 to 
2.3 mg/ day.
18,19
 Even when dietary levels of manganese are adequate, high dietary levels of fiber, phytate, 
ascorbic acid, iron, phosphorus, and calcium can limit the oral bioavailability and retention of manganese.
13,14,20-
23
 Suboptimal manganese status may also occur in humans with epilepsy, osteoporosis, or exocrine pancreatic 
insufficiency, individuals undergoing chronic hemodialysis, and in children with Perthes's disease or 
phenylketonuria.
1,24
 
 
Manganese Toxicity 
Manganese toxicity in humans is a well-recognized occupational hazard for people who inhale manganese dust. 
Inhalation of particulate manganese compounds (e.g., manganese dioxide [Mn02] or manganese tetroxide 
[Mn304]) leads to an inflammatory response in the lungs of animals and humans. Respiratory clinical signs and 
symptoms include cough, bronchitis, pneumonitis, and impaired pulmonary function.
25
 These effects may 
reflect an indirect response to inhaled particulate matter or may be associated with direct pulmonary toxicity 
induced by manganese.
6
 Impotence and loss of libido are another set of common symptoms observed in male 
workers with exposure to high concentrations of manganese.
6
 Although these effects are important, manganese-
induced neurotoxicity (manganism) is of greatest concern and is considered to be one of the most sensitive 
toxicological endpoints in people and animals. 
 
Air manganese concentrations reported to be associated with signs consistent with manganese neurotoxicity 
range from 0.027 to 1 mg Mn/m.
3,7,26-32
 These values represent estimates of actual exposure levels and provide 
limited dose-response information. Frank manganese neurotoxicity most commonly occurs in workers that have 
been chronically exposed to aerosols or dusts that contain extremely high levels (>1-5 mg Mn/m3) of 
manganese.
3,6,7
 Manganese-induced neurotoxicity may also occur following ingestion. Kawamura and 
coworkers
8
 and Kondakis et al.
9
 documented outbreaks of manganese toxicity in Japan and Greece, 
respectively, due to the consumption of water from wells contaminated with extremely high levels of 
manganese (1.8 to 14 mg Mn/L). More recently, Woolf et al. (2002)
33
 reported that a 10-year-old boy with 
abnormal verbal and visual memory function had elevated serum (0.90 μg/dl vs. normal value of <0.265 μg/dl), 
whole blood, urine, and hair manganese concentrations following chronic ingestion of well water containing 
modestly elevated levels (~1.2 ppm) of manganese. Along with the other reports already noted, this case 
suggests that children might be more sensitive than adults to excessive oral manganese exposures. 
 
Manganism is associated with elevated brain levels of manganese, primarily in those areas known to contain 
high concentrations of nonheme iron, especially the caudate-putamen, globus pallidus, substantia nigra, and 
subthalamic nuclei. Manganism is initially characterized by a psychiatric disorder (locura manganica) that 
resembles schizophrenia. Symptoms include compulsive and violent behavior, emotional instability, and 
hallucinations. Other early manifestations of manganese neurotoxicity include fatigue, headache, muscle 
cramps, loss of appetite, apathy, insomnia, and diminished libido.
3
 As exposure continues and the disease 
progresses, patients may develop prolonged muscle contractions (dystonia), decreased muscle movement 
(hypokinesia), rigidity, and muscle tremors.
3
 These signs are associated with damage to dopaminergic neurons 
within brain structures that control muscle movement. 
 
Individuals with manganism resemble patients with Parkinson's disease; however, these syndromes can be 
distinguished clinically.
3-5
 Similarities between Parkinson's disease and manganism include the presence of 
generalized bradykinesia and widespread rigidity. Dissimilarities between Parkinson's disease and manganism 
were also recognized, notably the following in manganism: (a) a less frequent resting tremor, (b) more frequent 
dystonia, (c) a particular propensity to fall backward, (d) failure to achieve a sustained therapeutic response to 
levodopa, and (e) failure to detect a reduction in fluorodopa uptake by positron emission tomography (PET).
3,5
 
Based on these differences, it has been proposed that manganese intoxication is associated with preservation of 
the nigrostriatal dopaminergic pathway, and that chronic manganese intoxication causes parkinsonism-like 
effects by damaging output pathways downstream of the nigrostriatal dopaminergic pathway.
3,5,34
 
 
Adverse effects of manganese on the developing nervous system are also a concern. There have been sporadic 
cases in which children with excessive exposure to manganese have developed signs of neurotoxicity.
33,35,36
 
When compared to adults, neonatal rodents are at an increased risk for manganese-induced neurotoxicity due to 
their ability to achieve higher brain manganese levels and altered brain dopamine concentrations following 
similar oral exposures.
37-40
 Known pharmacokinetic processes that may contribute to the increased susceptibility 
of neonatal animals include increased manganese absorption from the gastrointestinal tract, an incompletely 
formed blood—brain barrier, and reduced biliary manganese excretion in preweanling animals.
41-43
 The relative 
higher net increase in brain manganese concentrations in the neonates (vs. adults) should not necessarily be 
construed as evidence for heightened neurotoxicity in developing animals, given the known requirement for 
manganese for optimal CNS development in the neonate. Manganese concentration in the brain of developing 
rats is highest of all age groups, suggesting that manganese is required in a high amount during infancy, and that 
a sufficient manganese supply is critical for normal brain development.
44
 
 
A recent study by Dorman et al. (2000)
37
 assessed the relative sensitivity of neonatal and adult CD rats to 
manganese-induced neurotoxicity. Identical oral manganese chloride (MnCl2) doses (0, 25, or 50 mg/kg body 
weight/day) were administered to neonatal rats throughout lactation (postnatal day [PND] I though 21) and to 
adult male rats for 21 consecutive days. Increased striatal, cerebellar manganese concentrations were observed 
in adult rats from the high-dose group only. In contrast, increased striatal, hippocampal, hindbrain and cortical 
manganese concentrations were observed in all manganese-exposed neonates on PND 21. These results suggest 
that in the rat, manganese is more efficiently transported into the CNS of neonates compared to adults receiving 
equal oral doses of manganese. 
 
A substantial literature base exists regarding significant species differences in the neurotoxicity of manganese. 
Ex-posed monkeys retain manganese in their basal ganglia; they develop reduced concentrations of dopamine 
and certain dopamine metabolites (3,4-dihydroxyphenylacetic acid) in their striatum and pallidus, have 
decreased dopamine binding, and develop loss of dopaminergic neurons analogous to manganese-poisoned 
humans.
5,45-48
 However, similar regional brain manganese distribution, neurochemical, and neuropathological 
responses are not consistently observed in manganese-exposed rodents.
37,38,40,49-51
 Neither do rodents develop 
behavioral syndromes comparable to that seen in manganese-poisoned humans and monkeys.
52
 When 
considered together, these findings suggest that species differences confound the extrapolation of neurotoxicity 
results obtained for manganese in rodents to humans, possibly as a result of differential distribution of 
manganese in the CNS of rodents versus primates or due to intrinsic differences in tissue sensitivity in these 
various animal species. 
 
SOURCES OF MANGANESE 
Diet and Water 
The most important source of manganese for the general population is diet, with most daily intakes falling 
below 5 mg Mn/kg. Adult dietary intake of manganese has been estimated to range from 0.9 to 10 mg 
manganese/day.
6,18
 Manganese levels in excess of 30 mg/kg food can be found in grain, rice, and nuts. A cup of 
tea may contain as much as 0.4 to 1.3 mg manganese.
6
 Another important source of manganese intake is the 
consumption of manganese-containing dietary supplements, where each tablet can contain 5-20 mg of 
manganese.
14
 Water concentrations of manganese typically range from 1 to 100 μg/L with most values below 10 
μg/L.
53
 Based on the Total Diet Study, in adult males, grains, beverages (tea), and vegetables provide 
approximately 33, 20, and 18% of dietary manganese, respectively.
54
 The U.S. EPA has established an oral 
reference dose (RfD) for manganese (0.14 mg/kg-day; see http://www.epa.gov/iris/subst for additional 
information). 
Milk and Infant Formulas 
In general, milk is low in manganese; however, concentrations found in human and cow's milk can vary 
dramatically, with published values ranging from 3 to 120 and from 30 to 50 μg/L, respectively.
53,55-57
 This 
wide range of manganese concentrations may reflect in part different dietary levels of manganese. Manganese 
content in human (and animal) milk also varies with the stage of lactation
56-58 
(Table I). For example, Stastny 
and coworkers reported that mean (±SD) human milk manganese concentrations in the fourth week of lactation 
were 6.6 ± 4.7 μg/L, and these levels were significantly higher than those collected during the 12th week of 
lactation (3.5 ± 1.4 μg/L).
56
 Manganese intake in formula-fed infants is much higher than that observed in the 
breast-milk fed counterparts (Table 1) since levels of manganese in infant formulas may be substantially higher 
than that found in human milk.
59
 Nutritionists have recognized the risk posed by high manganese concentrations 
in infant formulas, and levels of manganese found in these formulas have changed dramatically over the last 20 
years. Prior to 1983, Enfamil (Mead Johnson and Company) contained 1289 μg Mn/L, while manganese levels 
dropped to 105 μg/L shortly thereafter.
56
 Despite these modifications, consumption of soy-based and other 
infant formulas remains a potential concern for human infants.
60
 
 
Airborne Manganese 
Although inorganic manganese compounds are not volatile, they can exist in air as fumes, aerosols, or 
suspended particulate matter.
6
 Atmospheric manganese derives from both anthropogenic and natural sources.
61
 
The wind erosion of dusts and soils and their subsequent reentrainment in the air contribute to airborne 
manganese. Industries associated with manganese emissions include ferroalloy production, iron and steel 
foundries, metal fumes from welding, battery production, and power plant and coke oven combustion 
emissions.
10
 Most human exposures remain below the current inhalation reference concentration (RfC) (0.05 μg 
Mn/m
3
) for inhalable manganese set by the U.S. EPA.
62-64
 Average levels of manganese in ambient air are 
approximately 5 and 33 ng Mn/m
3
 in nonurban and urban air, respectively,
6
 although air concentrations may be 
higher near ferromanganese or silicomanganese industries. The daily intake of manganese from the ambient air 
is estimated to be <2 μg Mn/day in the general population.
64-65
 
 
Manganese is also found in methylcyclopentadienyl manganese tricarbonyl (MMT), a fuel additive used in 
some unleaded gasolines. MMT is presently available in the United States, Canada, and other countries for use 
in fuel, replacing lead as a gasoline additive. Combustion of MMT by the automobile engine results in the 
formation and emission of a complex mixture of phosphate, sulfate, and oxide forms of manganese.
65-68
 The use 
of MMT in fuel has been the subject of much debate and review by regulatory agencies in Canada and the 
United States.
69-72
 
 
Air manganese concentrations from Toronto and Montreal, cities in which MMT has been widely used for over 
10 years, remain near or below the current inhalation reference concentration (RfC) (0.05 μg Mn/m
3
) for 
inhalable manganese set by the U.S. EPA.11,62-64 For example, the average atmospheric manganese 
concentrations measured in a high traffic area in Montreal were 0.050 and 0.024 μg/m
3
 for total and respirable 
fractions, respectively.
63,64
 In an area of much lower traffic density, total and respirable fractions were 0.027 and 
0.015 μg/m
3
, respectively.
63
 Personal exposures to manganese showed that the 99th percentile nonoccupational 
exposure to respirable manganese (PM2.5) in Toronto was 0.0215 μg Mn/m
3,11,62
 
 
Ambient manganese concentrations have also been measured in urban air where MMT is not used. For example, 
Pellizzari et al.
73
 have completed a smaller scale air-monitoring study in Indianapolis, a city where MMT is not 
used in gasoline. The levels of airborne manganese in Indianapolis were generally slightly lower than in 
Toronto. The median and mean levels for personal PM2.5 Mn exposures in Indianapolis were 0.0028 and 0.0075 
μg/m
3
, respectively, while the mean and median exposures for the nonoccupationally exposed group were 
0.0026 and 0.0031 μg/m
3
, respectively. Because there are many anthropogenic sources of environmental 
manganese, and the importance of these sources varies from city to city, it is not possible to ascribe all the 
differences in exposures between Toronto and Indianapolis to MMT. Moreover, it is unknown whether the 
difference in measured exposures in the two cities are statistically significant. 
 
Parenteral Exposure 
Individuals undergoing total parenteral nutrition (TPN) are at risk for manganese neurotoxicity. Parenteral 
nutrition solutions are sometimes formulated to include manganese.
74,75
 Wilson et al.
76
 found that manganese 
concentrations in TPN fluids ranged from 5.6 to 8.9 μg/L. 
 
Few studies have addressed the kinetics of manganese in the body upon TPN administration.
77
 Furthermore, no 
clear standard has been recommended for the daily dose of manganese, with the published literature indicating a 
broad, 200-fold range in the recommended daily manganese dose for adults, extending from a low dose of 0.18-
0.91 μmol (0.01-0.05 mg) to a high dose of 40 μmol (2.2 mg). 
 
Manganese intoxication associated with TPN solutions pro-viding 0.1 mg Mn/day have been reported.
46,78,79
 As 
with other forms of manganese poisoning, these patients developed elevated serum manganese level, they had 
symmetrical high-intensity magnetic resonance imaging (MRI) lesions in the globus pallidus consistent with 
manganese accumulation at this site, and they developed characteristic psychiatric symptoms and clinical signs 
of manganese-induced neurotoxicity.77 Withdrawal from the TPN supplement significantly decreased 
manganese levels in both the blood and brain.
78,80
 
 
Another potential source of manganese exposure is the inclusion of manganese in radiological contrast agent.
81 -
83 
In each of these cases, parenteral exposure may pose a much higher risk for manganese toxicity since the 
bioavailability of manganese in parenteral fluids is much higher than that observed following oral exposure 
(100 vs. ~5%). Moreover, normal regulation mechanisms for manganese metabolism are largely bypassed, and 
there is a greater danger of toxicity. Infants and adults with hepatic insufficiency are at an even greater risk for 
developing increased serum or tissue manganese concentrations when kept on prolonged parenteral nutrition.74 
 
Other Sources 
Humans may also be exposed to organic manganese-containing pesticides, such as manganese ethylene-bis-
dithiocarbamate (Maneb).
84
 Another potential source of manganese exposure is the street drug "Bazooka," 
which is a cocaine-based street drug contaminated with manganese carbonate.
85
 
 
 
 
MANGANESE ABSORPTION 
Oral Absorption 
Only a small fraction (1-5%) of ingested manganese is normally absorbed into the body.
86
 Most estimates of net 
gastrointestinal absorption of manganese in humans have been based on studies evaluating the whole-body 
retention of radiolabeled manganese (
54
Mn) several weeks after an oral exposure to a tracer dose of 
54
Mn. 
Finley and coworkers15 estimated that net gastrointestinal absorption (mean ± SD) of manganese from a meal 
containing 1 mg manganese was 1.35 ± 0.51% and 3.55 ± 2.1 % for adult men and women, respectively. 
Davidsson et al.
87
 found that mean (±SD) retention 10 days after ingestion of approximately 0.3 mg manganese 
was 5.0 ± 3.1% in young adult women. In contrast, oral tracer studies that evaluate the retention of manganese 
less than 24 h after manganese ingestion reveal a much higher initial retention of the ingested dose. Animal 
studies conducted with diets spiked with a tracer dose of 
54
Mn confirm that much of the retained manganese is 
found in the liver and the intestinal tract. The majority of this manganese does not become available to systemic 
tissues. 
 
The mechanism by which manganese is absorbed from the gastrointestinal tract is not completely understood. 
Some studies suggest that manganese is absorbed through an active transport mechanism.
88
 Other investigators 
have shown that manganese absorption may occur via a nonsaturable process consistent with passive 
diffusion.
89
 Under normal conditions, the manganese arriving at the liver in the portal circulation is protein 
bound. Within the plasma approximately 80% of manganese is bound to β-globulin and albumin, and a small 
fraction of trivalent (3+) manganese is bound to the iron-carrying protein transferrin.
90,91
 
 
Manganese absorption from the gastrointestinal tract is extremely complex, and a number of factors can 
influence manganese absorption and retention. The concentration of manganese in the diet is known to 
influence the amount of manganese absorbed from the gastrointestinal tract and the amount of manganese 
eliminated in the bile. When dietary manganese levels are high, adaptive changes include reduced 
gastrointestinal absorption of manganese, enhanced manganese liver metabolism, and increased biliary and 
pancreatic excretion of manganese.
18,86,92-97
 For example, the relative amount of manganese absorbed from the 
gastrointestinal tract decreased as the dietary manganese concentration increased from 4 to 2000 ppm.
98
 Abrams 
et al. (1976)
98
 also showed decreased manganese retention (expressed as the percent dose per gram tissue) in the 
liver, kidney, spleen, and other systemic tissues as the concentration of manganese in the diet increased. 
 
Davidsson et al.
99
 demonstrated that the fractional manganese absorption from human milk was significantly 
higher than that observed in adult volunteers given a soy-based diet (8.2 ± 2.9 vs. 0.7 ± 0.2%) that provided 132 
μg manganese (vs. 7.2 μg Mn in the human-milk diet). Net manganese absorption from the diet is also 
influenced by the presence of other trace minerals, phytate, ascorbic acid, and other dietary constituents.
20
 The 
potential for manganese—nutrient interactions in the gastrointestinal tract makes it difficult to predict the 
delivered dose of manganese arising from a given dietary exposure. 
 
Manganese absorption may in part involve complex interactions with other minerals.
100
 Lai et al. used a 
developmental rat model of chronic manganese toxicity to evaluate these nutrient interactions.
100
 Lai and 
coworkers treated neonatal rats with a high concentration of manganese chloride (20 mg MnC12/ml drinking 
water) throughout development until adulthood.
100
 Administration of manganese in drinking water was 
associated with increased levels of iron, copper, selenium, zinc, and calcium in various regions of the brain. 
Planells et al. demonstrated that enterocytes from Wistar rats maintained on a magnesium-deficient diet (129 
mg Mg/kg food for 70 days) had higher manganese concentrations when compared with control animals fed a 
diet that met nutritional requirements for magnesium (480 mg Mg/kg food).
101
 Davidsson et al. demonstrated an 
inverse relationship between manganese absorption and the concentration of calcium found in human milk.
20
 
Although these interactions are important, manganese interactions with iron have been the most extensively 
studied. Animal studies have demonstrated that iron deficiency enhances manganese absorption across the 
gastrointestinal tract, independent of body manganese stores.
102,103
 An inverse association between body iron 
stores and manganese absorption has also been demonstrated in humans.
104
 Competition between manganese 
and iron for intestinal absorption
105
 likely occurs by way of divalent metal transporter 1, referred to as DMT-1 
(also known as DCT- 1 or nramp-2).
106
 Functionally, DMT-1 mediates the intestinal uptake of numerous 
divalent metal cations, and DMT-1 mRNA levels in the duodenum strongly increase in response to iron 
depletion. 
107
 Studies in Caco-2 cells, in an in vitro model of the gastrointestinal epithelium reveal that iron 
treatment decreases cellular uptake of both iron and manganese (as well as zinc), suggesting that these metals 
may utilize the same apical and basolateral transporters.
108
 
 
Manganese absorption from the gastrointestinal tract is also influenced by age. Studies conducted in suckling rat 
pups show that manganese absorption is very high during the neonatal period.
109,110
 Rat pups younger than 15 
days of age given human milk labeled with 
54
Mn retained approximately 80% of their oral exposure dose 6 h 
after ingestion. Older rats (> 16 days of age) had reduced initial manganese retention of approximately 40% of 
the administered oral dose. Human infants also have higher retention of ingested manganese during the early 
neonatal period.
111,112
 Manganese retention in formula-fed term infants was approximately 20%.
112 
The 
developing brain takes up a significant proportion of the manganese retained by the body during the early 
neonatal period. For example, Keen and coworkers report that approximately 87o of the total oral manganese 
dose is retained in the brain by rats.
110 
These age-dependent changes may reflect reduced control by the 
gastrointestinal and hepatobiliary systems or the lower body burden of manganese present in neonatal animals. 
 
Respiratory-Tract Absorption 
There are a limited number of studies that have evaluated manganese absorption from the lung. No studies were 
located regarding the absolute amount of manganese that is absorbed by humans or animals after inhalation 
exposure to manganese dusts. There are a number of factors that influence pulmonary deposition of inhaled 
manganese particles. Particle size heavily influences the site at which manganese particles are deposited 
within the respiratory tract. Lung deposition is favored following the inhalation of particles less than 0.1 μm in 
size as well as those ranging in size from 0.8 to 3 μm. The soluble fraction of manganese particles deposited in 
the lower airways may be absorbed from the lung, while insoluble components may be cleared or translocated 
to other sites within the respiratory system. Particle translocation may lead to pulmonary toxicity at those other 
sites. The rate at which manganese is absorbed from the lung may influence brain and other organ manganese 
delivery. In a study by Rhoads and Sanders,
113
 for instance, a number of metal compounds that were more 
rapidly absorbed from the lungs were retained for longer time periods at other sites in the body where they 
could potentially exert their effects. Larger manganese particles that are deposited in the upper airways may be 
transported by mucociliary transport to the throat where they are subsequently swallowed and a fraction of this 
ingested manganese can be absorbed. Manganese particles that deposit in the nose can also be absorbed or 
cleared. One site where nasal absorption occurs is at the olfactory epithelium. Inhaled manganese absorbed by 
the rat olfactory epithelium can undergo transport along the olfactory nerve to the olfactory bulb.
114-116
 Cellular 
mechanisms involved with manganese absorption within the respiratory tract are unknown. 
 
Absorption of manganese deposited in the lung is influenced by particle solubility. Roels et al.
117
 measured 
blood manganese levels in 3-month-old rats following intratracheal administration of a relatively soluble 
(MnC12) or insoluble (MnO2) form of manganese (administered at 1.22 mg Mn/kg). Peak blood levels occurred 
following MnC12 instillation within 30 min, whereas a similar dose of MnO2 did not reach peak blood 
manganese levels until 7 days following instillation, suggesting that the insoluble form is less bioavailable. 
Manganese levels in blood following MnC12 and MnO2 dosing reached a maximal level of 7050 ng/dl at 30 min 
and 760 ng/d1 168 h following administration, respectively. Roels et al.
117
 also showed that more soluble forms 
of manganese (e.g., MnC12 vs. MnO2) given to 3-month-old rats via intratracheal instillation are more readily 
delivered to the brain. Dorman and coworkers
118
 showed that lung manganese concentrations were higher in rats 
exposed to a soluble form of manganese (e.g., MnSO4) when compared with levels seen following inhalation of 
considerably less soluble manganese particles like the phosphate or tetroxide forms. This finding is consistent 
with enhanced pulmonary absorption of manganese from the more soluble MnSO4 particle. Moreover, animals 
exposed to high levels (3 mg Mn/m
3
) of MnSO4 have significantly higher striatal, testes, and liver manganese 
concentrations when compared with levels achieved following exposure to the insoluble tetroxide (Mn304) form. 
These studies confirmed that brain uptake of inhaled manganese is similarly influenced by particle solubility. 
 
Dermal Absorption 
No studies were located regarding absorption in humans or animals after dermal exposure to manganese. It is 
generally assumed that uptake of manganese across the intact skin is very limited.
6
 
 
MANGANESE DISTRIBUTION (EXCLUDING BRAIN)  
Manganese Transport Proteins in Blood 
No unique mammalian transporters are known for manganese. The affinity of divalent manganese toward 
endogenous ligands is relatively low. It does not avidly complex with sulfhydryl (—SH) groups or amines, and 
it shows little variation in its stability constants for endogenous complexing ligands such as glycine, cysteine, 
riboflavin, and guanosine. Within the plasma, approximately 80% of manganese is bound to globulin and 
albumin, and a small fraction of trivalent manganese is bound to transferrin.
90,91,119
 At normal plasma iron 
concentrations (0.9-2.8 μg/ml), iron-binding capacity (2.5- 4 μg/ml), and transferrin concentration (3 mg/ml, 
with 2 metal-ion-binding sites per molecule [Mr 77000], of which only 30% are occupied by trivalent iron), 
transferrin has 50 μmol/L of unoccupied trivalent manganese binding sites, and has, there-fore, been implicated 
as a potential transporter for manganese across the blood-brain barrier and other membranes (discussed later).
120
 
 
Subcellular Localization of Manganese 
At physiological levels, manganese specifically concentrates in mitochondria,
121-123
 where it most likely 
complexes with ATP. With exposure to excess manganese, Liccione and Maines
124
 demonstrated a two-fold 
greater increase in manganese in the mitochondria! fraction of the stritum than that of the whole brain. 
Brenneman and coworkers
49
 did not find selective uptake of manganese in the mitochondrial fraction of the 
striatum or cerebellum from neonatal rats that were given high doses of manganese (0, 25, or 50 mg 
MnC12/kg/day) from birth throughout early adulthood (postnatal day [PND] 1 to 49). In the Brenneman study, 
selective uptake was defined as an increase in the percentage of total regional manganese in the mitochondrial 
fraction with exposure to excess manganese. Brenneman et al.
49
 concluded that if this percentage is not altered 
with increased tissue levels of manganese, then the normal distribution of manganese is being maintained, and 
selective uptake has not occurred. It appears more accurate, in light of the findings re-ported by Brenneman et 
al.
49
 to state that chronic manganese administration increases mitochondrial manganese concentrations but does 
not markedly change the relative proportion of cellular manganese found in the mitochondrial fraction.
49
 Lai et 
al. reached a similar conclusion for a wide range of brain subcellular fractions.
125
 
 
Systemic Manganese Distribution 
Manganese is found in all mammalian tissues with concentrations ranging from 0.3 to 2.9 μg manganese/g wet 
tissue weight and there is little variation among species with regard to tissue manganese concentrations (Table 
2).
41,53
 Tissues rich in mitochondria and pigments (e.g., retina, dark skin) tend to have high manganese 
concentrations. Bone, liver, pancreas, and kidney typically have higher manganese concentrations than other 
tissues. The largest tissue store of manganese is in the bone. Tissue manganese concentrations in normal and 
manganese-exposed individuals are discussed in greater detail later in this review. 
 
Manganese Distribution Across the Placenta 
In vitro studies have suggested that the human placenta accumulates manganese and that the bidirectional 
transfer of manganese across the placenta is low.
126 
In vivo rodent studies using oral gestational exposure have 
further demonstrated that the amount of manganese that crosses the placenta is low.
127
 Despite this apparent 
barrier, fetotoxicity (reduced fetal body weight or structural anomalies) in the absence of maternal toxicity has 
been reported to occur in mice exposed orally to high levels of manganese.
128-130 
 
Few studies have examined fetal manganese tissue concentrations in humans. Casey and Robinson (1978)
131
 
reported that manganese concentrations in a variety of tissues obtained from 40 human fetuses ranged from 0.35 
to 9.27 μg Mn/g dry weight. In vivo studies in laboratory animals have shown that ingested manganese can 
accumulate in the fetal brain following gestational exposure.
50
 Placental delivery of manganese also occurs in 
rats following inhalation exposure with elevated fetal liver (but not brain) manganese concentrations being 
observed (Dorman, et al., in press [Neurotoxicology]). 
 
 
The mechanism involved in manganese distribution across the placenta is unknown; however, both transferrin 
and DMT-1 may be involved. Data in support of this hypothesis include the findings that transferrin and DMT-1 
are present in the placenta and that placental transferrin and DMT-1 are upregulated in maternal iron deficiency, 
thus minimizing the severity of fetal anemia.
132
 Considering the potential shared function of DMT-1 and 
transferrin in transport of iron and manganese, maternal iron deficiency may lead to enhanced placental delivery 
of manganese to the fetus. DMT-1 is found in the developing brain, and DMT-1 mRNA has been shown by in 
situ hybridization to localize to the rat striatum, cortex, hippocampus, and cerebellum at an early gestational 
age.
133
 
 
MANGANESE DISTRIBUTION TO THE CNS 
Regional Delivery of Manganese Within the Brain 
The use of MRI techniques has revealed that manganese-poisoned humans and macaque monkeys develop 
elevated striatum, globus pallidus, and substantia nigra brain manganese concentrations.
5,46,47,134
 In contrast, 
experimental studies have failed to clearly establish that the rodent striatum and globus pallidus preferentially 
accumulate manganese following high-concentration manganese exposure (see Brenneman et al. for review
49
). 
 
 
Mechanisms Involved With the Delivery of Manganese Across the Blood—Brain Barrier 
A limited number of studies have addressed the transport kinetics of manganese from the blood into the CNS. 
Collectively, these studies suggest that manganese enters the brain from either across the cerebral capillaries 
and/or the cerebrospinal fluid (CSF; via choroid plexus transport), or via the olfactory nerve. Each of these 
transport scenarios is discussed in detail later. At normal plasma concentrations, transport across the capillary 
endothelium predominates, whereas at high plasma concentrations, transport across the choroid plexus appears 
more prevalent.
135,136
 
 
Studies using bolus intravenous manganese injections have demonstrated efficient transport of divalent 
managanese across the blood—brain barrier. These studies showed that manganese transport into the brain was 
transferrin independent, affected by plasma protein binding, and most likely reflects the transport of manganese 
as the free ion.
135-139
 Collectively these studies suggest that manganese transport across the blood—brain barrier 
is facilitated by either an active or a passive mechanism governed by a saturable process.
135,139
 Since the 
increase in brain concentrations via blood following a bolus injection is different from that noted via the 
redistribution from the liver,
138
 caution must be exercised in extrapolating from these studies to the contribution 
of the saturable transport of divalent manganese in physiological conditions. To date, studies on the 
mechanisms of manganese transport across the blood—brain barrier have focused on transferrin- and DMT-1 
mediated transport, but the possibility of transport modulation by other transporters cannot be excluded. 
 
A number of studies substantiate the role of transferrin in manganese uptake across the blood—brain barrier. In 
vitro, endocytosis of a manganese—transferrin complex in cultured neuroblastoma cells (SHSY5Y) has been 
noted.
140
 A time-dependent increase in 
54
Mn uptake in the rat brain has also been described,
141
 likely reflecting 
capillary endothelial transport of manganese in the trivalent (Mn
3+
) oxidation state. However, the internalization 
of manganese—transferrin complexes into brain capillary endothelium has yet to be demonstrated. 
 
The hypotransferrinemic (hpx/hpx) mouse in which a genetic defect results in <1% of normal plasma transferrin 
concentration has provided a unique opportunity to examine the role of transferrin in manganese and iron 
transport into the CNS. The hpx/hpx mouse is the result of a spontaneous mutation, and it has an mRNA 
splicing defect resulting in virtually no synthesis of transferrin protein.
142
 No difference was found in total brain 
uptake of iron or manganese upon intraperitoneal or intra-venous injections of 
59
FeC13 or 
54
MnC12, 
respectively, between +/+ (controls) and hpx/hpx mice.
143,144 
Striking differences in regional distribution were 
noticed for 
59
Fe, but only subtle differences in the distribution of brain 
54
Mn,
145
 consistent with the transferrin 
receptor system being the predominant mechanism for iron delivery to the brain. Slightly lower levels of 
54
Mn 
in cerebral cortex and corpus collosum were observed in the hpx/hpx mice relative to +/+ controls. Although 
transferrin-receptor-mediated transport appears less important for delivery of manganese to the brain in hpx/hpx 
mice,
146
 it must be considered that transferrin-independent mechanisms (such as DMT-1 discussed later) might 
be unmasked by the genetic defect, thus compensating for hypotransferrinemia. Consistent with this possibility 
are studies by the same authors
144
 in which transferrin was required for normal distribution of 
59
Fe and 
54
Mn in 
brains of "normal" mice. 
 
Transferrin receptors have been identified at the surface of the cerebral capillaries.
147
 Manganese may be 
transported from high-density transferrin receptor expressing regions
148
 by means of axonal transport. Indeed, 
the nucleus accumbens and the caudate-putamen, two brain nuclei that are abundantly rich in transferrin 
receptors, provide efferent fibers to areas that are rich in manganese, such as ventral-pallidum, globus pallidus, 
and substantia nigra. Manganese can also be transported along nerve fibers (by means of axonal transport) in the 
olfactory pathway, optic nerve, and brain parenchyma.
114,149-153
 
 
There is growing evidence that DMT-1 is involved in brain manganese delivery.
154
 In the microcytic anemia 
(mk) mouse and the phenotypically similar Belgrade (b) rat,
155-157 
orthologous mutations (glycine 185 to 
arginine) in the DMT- I gene result in significantly reduced dietary iron absorption. The role of the defective 
DMT- I allele in the transport of manganese across the blood-brain barrier has been recently evaluated in 
homozygous Belgrade (b/b) rats that exhibit hypochromic anemia and heterozygous (-Fib) Belgrade rats.
158
 
Plasma clearance and up-take by the CNS after intravenous injection of radioactive 
54
Mn bound to transferrin or 
mixed with serum have demonstrated that plasma clearance of manganese-transferrin was much slower than 
manganese-serum, but both were faster than the clearance of iron-transferrin. Uptake of 
54
Mn, as well as 
59
Fe by 
the brain was less in b/b than +/b rats, suggesting that the defective DMT- I allele affects the distribution of both 
metals, and that manganese and iron might share DMT- 1 transporters in the blood-brain barrier.
158
 
 
While the majority of studies suggest that manganese and iron compete for the same carrier, it should be also 
pointed out that manganese and iron transport from the plasma to the brain has been postulated to be synergistic 
rather than competitive in nature, and that excessive intake of iron plus manganese may accentuate the risk of 
tissue accumulation of the second meta1.
159
 These studies suggest that manganese dosimetry is complex and 
that multiple pathways are involved in delivery of manganese to the brain. 
 
Manganese Delivery Across the Choroid Plexus 
The choroid plexus is potentially an important site for brain delivery of manganese. This structure is where 
injected 
54
Mn first appears in the rodent brain.
145,153
 The regulation of substrate entry into the brain via choroid 
plexus synthesis of cerebrospinal fluid (CSF) is different from that at the blood-brain barrier. Capillaries in the 
choroid plexus are fenestrated, and substances must first be taken up by choroid plexus epithelium. This 
epithelium then secretes CSF. Eventual neuronal uptake of substances from CSF must proceed via the 
ependymal cells. It is thought that tanycytes of the ependyma might play an important role in delivery of non-
transferrin bound iron to the hypothalamus.
160
 London et al.
161
 reported a rapid localization of manganese in the 
choroid plexus observed on MRI; similarly, radiotracer studies of manganese injected into the intracerebro-
ventricular space revealed that radiolabeled manganese was located in the choroid plexus within 1 h and was 
located in the rat dentate gyrus and CA3 of the hippocampus 3 days postdosillg.
149
 Murphy et al.
135
 measured 
the kinetics of manganese transport in the brains of adult male rats following intravenous infusion with 
54
MnCl2. This experiment revealed that transport of Mn
2+
 into the choroid plexus was dependent upon a 
saturable mechanism. At all plasma manganese concentrations tested (from 0.8 to 78 nmol/ml), the transfer 
coefficient for manganese uptake into the choroid plexus was significantly higher than in any other area of the 
CNS. For example, at 0.08 nmol/ml, the transfer coefficients for the CSF and the choroid plexus were 16.2 ± 
2.43 • 10
-6
 ml/sec x g and 23, 800 ± 2910 • 10-6 ml/sec x g, respectively. Even after correcting for differences in 
compartment size, influx of manganese into the choroid plexus was an order of magnitude greater than influx 
into CSF. 
 
Olfactory Nerve Delivery of Manganese 
The olfactory system forms a direct interface between the nervous system and the external environment. Certain 
xenobiotics can bypass the systemic circulation and gain access to the brain and/or CSF directly following nasal 
administration.163 Three major pathways could facilitate the movement of a xenobiotic from the nose to the 
brain, including ( 1 ) an olfactory nerve pathway, (2) an olfactory epithelial pathway (independent of the 
olfactory receptor neuron resulting in transport to the brain along the perineuronal space around the olfactory 
nerve), and (3) a systemic pathway secondary to movement from the nasal epithelium to the blood in the 
submucosal space.
163
 
 
Recent research results suggest that direct intraaxonal transport of manganese must be considered when 
evaluating brain delivery of inhaled manganese (reviewed by Tjiilve and Henriksson
164
). Olfactory transport of 
manganese occurs in the rat, mouse, and freshwater pike following intranasal instillation.
149,164,165
 After 
intranasal instillation, manganese can migrate to most parts of the brain through its ability to jump neuron 
synapses and travel along secondary and tertiary neurons.
166
 Elevated brain concentrations of manganese were 
detected 12 h following one-sided intranasal instillation of manganese chloride by Gianutsos et al.
149
 With 
multiple injections, these investigators were able to see increased manganese concentrations in the striatum as 
well, demonstrating that manganese is able to reach the striatum under certain exposure conditions.
149
 Dose 
dependency of the transport of manganese from the olfactory epithelium to the olfactory bulb was further 
demonstrated following intranasal administration of manganese chloride.
150
 This propensity to travel along 
secondary or tertiary neurons noted with manganese is not observed with cadmium and other metals.
164
 
 
Until recently, little was known regarding the olfactory trans-port of manganese following inhalation exposure. 
Brenneman and coworkers
114
 and Dorman et al.
115
 conducted studies in rats using short-term (90-min) 
inhalation exposure to either a water-soluble (
54
MnCl2) or insoluble (
54
MnHPO4) manganese aerosols. These 
investigators used an animal model in which one nostril was occluded, thus restricting olfactory transport of 
manganese to the side of the rat brain on the other side to the patent nostril. In these studies, direct delivery 
along the olfactory route accounted for nearly all the 
54
Mn found in the olfactory bulb and tract of the rat brain 
following acute 
54
MnCl2 or 
54
MnHPO4 inhalation. 
 
Similar aerosol concentrations (0.54 vs. 0.39 mg Mn/m
3
 for the 
54
MnCl2 and 
54
MnHPO4 exposures, 
respectively) and particle sizes (2.51 vs. 1.68 μm for the 
54
MnCl2 and 
54
MnHPO4 exposures, respectively) were 
used in these studies. Manganese clearance from the olfactory epithelia was slower following exposure to 
manganese phosphate when compared to the more soluble chloride salt.
115
 In addition, a smaller fraction of the 
54
Mn initially deposited on the olfactory epithelium was found in the olfactory bulb one day after the end of the 
54
MnHPO4 exposure. The finding of decreased olfactory epithelial clearance and reduced olfactory bulb 
delivery following manganese phosphate inhalation is consistent with the results of longer term (2-week) 
inhalation experiments with soluble and insoluble manganese salts.
115
 Dorman and coworkers
115
 showed that 
inhalation exposure to soluble forms of manganese (e.g., manganese sulfate) resulted in higher olfactory bulb 
manganese concentrations than those achieved following exposure to a relatively insoluble form of manganese 
(e.g., manganese phosphate or tetroxide). Thus, the olfactory route may be a significant pathway by which 
manganese gains access to certain regions within the rat brain. 
 
Fechter et al.
116
 examined whether particle size could influence brain delivery of inhaled manganese. These 
investigators exposed juvenile Long-Evans rats to an insoluble form of manganese (MnO2). Inhalation 
exposures were conducted for 6 h/day, 5 days/week, for 3 weeks. Fechter et al.
116
 exposed animals to either air 
or MnO2, at 3 mg Mn/m
3
. Two different-sized manganese particles were used (mass median aerodynamic 
diameter [MMAD] of 1.3 and 18 μm) in this experiment as well. End-of-exposure olfactory bulb manganese 
concentrations were approximately 1.5, 2.6, and 1.6 μg/g for rats exposed to either air, fine particles (1.3 μm), 
and coarse particles (18 μm), respectively. Although olfactory-bulb concentrations were elevated in rats 
exposed to the 1.3-μm particles, this increase was not statistically significant. Results of Fechter et al.
116
 suggest 
that particle size may influence delivery of manganese to the rat olfactory bulb because manganese delivery 
appeared to be smaller for the large particles (18 μm). This study must be interpreted with caution; however, 
since Fechter et ai.
116
 also showed that lung manganese concentrations were approximately 2.5 and 1.6 μg Mn/g 
for rats exposed to the 1.3- and 18-μm particles, respectively. Although marginally inhalable, an 18-μm particle 
would not be expected to be deposited beyond the nasopharynx in the rat.
168,169
 The lung manganese 
concentrations reported in this study following exposure to the 18-μm particle are therefore inconsistent with 
the particle size distribution presented by these investigators. 
 
The toxicological significance of olfactory transport of manganese remains controversial. Although olfactory 
transport rapidly delivers manganese to brain structures in the olfactory pathway, it is relatively slow (or 
incapable) at delivering manganese to the striatum and other more distant brain structures.
114,115,166 
Henriksson 
and Tjalve
167
 found that intranasal instillation of manganese results in alterations in olfactory bulb expression of 
glial fibrillary acidic protein and S- 100b in rats. These proteins are known markers of damage to astrocytes, an 
important support cell found within the CNS. Manganese exposure by humans has been associated with 
olfactory deficits (manganese-enhanced olfactory sensitivity); whether these alterations are linked to direct 
olfactory uptake remains unknown.
7,170
 
 
The relevance of nasal uptake studies conducted in rats to human manganese inhalation exposure is unknown. 
Significant interspecies differences in nasal and brain anatomy and physiology exist.
171
 In the rat, the olfactory 
bulb accounts for a relatively large portion of the CNS, and the nasal olfactory mucosa covers approximately 
50% of the total nasal epithelium. These structures are proportionately smaller in primates; for example, the 
olfactory mucosa covers approximately 5% of the total nasal epithelium in humans. These anatomical 
differences argue that this route of brain delivery may be less important in humans as compared to the rat. In 
addition, total airflow to the olfactory mucosa is slightly lower in humans than in rats.
172,173
 These differences 
may predispose the rat, more so than humans, to olfactory deposition and potential olfactory transport of 
manganese; however, direct experimental evidence in support of this conclusion is lacking. Furthermore, the 
experimental animal inhalation studies that have been conducted to date are short-term, relative to the chronic 
exposures of occupational and nonoccupational populations. 
 
Factors That Influence Brain Manganese Delivery 
Consistent with the hypothesis of shared transporters for manganese and iron are observations that plasma iron 
over-load significantly decreases brain manganese levels.
120,174,175 
Conversely, brain manganese levels are 
elevated with decreased plasma iron concentrations.
144,176-178
 
 
A recent study performed by the Aschner laboratory
176
 examined the effects of both marginal iron deficiency 
(ID) (in the absence of anemia) and manganese fortification (CNMn+ diet) on manganese accumulation in the 
rat brain. Hemoglobin and hematocrit levels (141 g/L and 40To, respectively) revealed that the iron deficient 
rats were not anemic; however, plasma transferrin concentrations were indicative of iron deficiency (i.e., 
significantly higher than controls). A significant increase in manganese concentrations across brain regions in 
iron-deficient rats consuming high manganese diet (100 ppm; IDMn +) was noted. Highly fortified manganese 
diet (100 ppm) in iron-replete rats, and "normal" manganese diet (10 ppm) in iron-deficient animals did not lead 
to changes in brain manganese levels com-pared with controls. These studies are consistent with increased brain 
manganese accumulation (in rodent experimental models) in conditions of iron deficiency. 
 
The route of exposure can influence the delivery of manganese to the CNS.
12,117
 Roels et al.
117
 investigated 
brain manganese concentrations in rats following exposure to either a soluble (MnCl2) or insoluble (MnO2) 
form. These chemicals were administered via intratracheal injection (as a surrogate for in-halation) or by gavage 
(i.e., oral administration). This experiment was designed in order to achieve similar blood manganese 
concentrations and was thus designed to account for low oral absorption of manganese versus the higher rate of 
absorption from the lung. When administered intratracheally once a week for 4 weeks, 1.22 mg manganese/kg 
as MnCl2 resulted in a 68% steady-state increase in blood manganese concentration after the dosing period. This 
dose also resulted in significantly increased concentrations of manganese in the rat striatum (205% increase) 
and cortex (48% increase) when compared to control rats. Ad-ministration of manganese as MnCl2 by gavage 
(administration of 24.3 mg manganese/kg as MnCl2 once weekly for 4 weeks) caused roughly the same amount 
of increased manganese in the blood (68% increase vs. controls) as intratracheal administration of manganese in 
the same form, but it did not cause as significant an increase of manganese in the cortex (22% increase vs. 
controls).
117
 Striatum manganese concentrations were unaffected following gavage administration of 
manganese. Thus, pulmonary delivery of manganese appears to be more efficent than ingestion in increasing 
manganese concentration in the brain. 
 
Pharmacokinetic factors that may contribute to the increased efficiency in brain manganese delivery observed 
after inhalation exposure include increased manganese absorption from the respiratory tract, slower blood 
clearance of absorbed manganese, and direct olfactory transport of manganese to the brain.
12
 
 
MANGANESE TRANSFORMATION 
Manganese does not undergo metabolism; as its elemental form, it is absorbed and excreted unchanged. 
However, manganese can exist in a number of oxidation states, and it can undergo changes in its valence states 
within the body. Measurements of unpaired electrons in Mn
2+
, Mn
3+
, and Mn
4+
 complexes found in tissues and 
fluids using electron spin resonance (ESR) has been used to evaluate valence forms of manganese in biological 
media. When animals were injected with divalent manganese (as MnCl2), levels of manganese increased in bile 
and tissues, but only a small portion of this was in a form that gave an ESR signal.
179-180
 This finding suggests 
that Mn
2+
 is converted to another oxidation state (probably Mn
3+
), but it is also possible that formation of 
complexes between Mn
2+ 
and biological molecules (bile salts, proteins, nucleotides, etc.) results in loss of the 
ESR signal without formal oxidation of the manganese ion. The form of manganese in most enzymes is Mn3+, 
while most manganese taken into the body exists as either the Mn
2+ 
or Mn
4+
 forms. Mn
2+
 is the predominant 
form in biological systems. 
 
Gibbons et al.
181
 reported that human ceruloplasmin led to the oxidation of Mn
2+
 to Mn
3+
 in vitro. This pathway 
has been considered a possible mechanims for manganese oxidation in blood. Gibbons et al.
181
 also reported 
that manganese oxidation led to a shift in the in vitro binding of manganese from α2- macroglobulin to 
transferrin. The valence state of manganese may also influence its disposition in the body. Komura and 
Sakamoto
182
 showed that distribution of an insoluble tetravalent (e.g., MnO2) and soluble divalent (MnCl2) 
forms of manganese to the cerebral cortex differed following manganese ingestion. They found that less soluble 
forms such as MnO2 were taken up to a significantly greater degree in cerbral cortex than the more soluble 
MnCl2 form. However, these investigators showed that the corpus striatal binding characteristics of the +4 
valence state of manganese in MnO2 were not substantially different from those of the divalent forms in MnCl2. 
Roels et al.
117
 also found differences in manganese concentrations in blood and brain regions depending on the 
initial oxidation state of the metal. Manganese metabolism or initial valence states may be an important 
determinant of manganese retention in the body.
6
 
 
The valence of manganese and hence its metabolism may also influence the toxicity of manganese. In vitro 
Mn
3+
 appears to be more cytotoxic than Mn
2+
 species, possibly due to higher oxidative reactivity and a closer 
radius resemblance to iron.
183
 The enhanced ability of trivalent manganese to induce oxidative stress has been 
confirmed in rats given either manganese chloride (Mn
2+
) or manganese acetate (Mn
3+
).
184
 Oxidation of 
important cellular components by trivalent manganese (Mn
3+
) might represent the primary means by which 
manganese mediates cellular damage. However, it is currently unknown how much intracellular (and 
intramitochondrial) manganese is in the divalent versus trivalent forms. 
 
MANGANESE EXCRETION 
Estimation of Manganese Excretion Rates 
Administration of a 
54
Mn tracer can be used to determine whole-body elimination of manganese and indirectly 
assess liver manganese metabolism. In animals and humans, the whole-body elimination of a single tracer dose 
of 
54
Mn is biphasic,
92,95,97
 and the rates of elimination can be altered by dietary and inhaled manganese intake 
rates.
93
 The rapid-phase elimination rate constant and the proportion of the tracer dose eliminated in the rapid 
phase increases with increasing rates of manganese ingestion.
92,185
 Dose-dependent elimination of a trace dose 
of 
54
Mn has been observed in manganese-exposed miners when compared to occupationally unexposed 
humans.
186
 
 
Biliary Excretion 
Biliary excretion is the main pathway by which manganese reaches the intestines where most of the element is 
ultimately excreted in the feces.
86,96
 Regardless of manganese intake, adult humans generally maintain stable 
tissue levels of manganese. The basis for this homeostatic mechanism is the regulation of both absorption and 
excretion rates for manganese.
6
 Absorbed manganese is removed from the blood by the liver and is excreted 
into the intestine via the bile. Some of the manganese in the intestine is reabsorbed through enterohepatic 
circulation.
187
 The rate of biliary excretion of manganese is influenced by a number of factors. 
 
Lee and Johnson
188
 reported that the rate of 
54
Mn excretion was significantly accelerated in rats by increased 
dietary manganese concentrations, while the efficiency of 
54
Mn absorption was decreased by increasing dietary 
manganese concentrations. Thus, the fraction of ingested manganese retained by the body is regulated in order 
to maintain normal tissue manganese concentrations under different dietary conditions. 
 
Dorman et al.
118
 and Vitarella et al.
189
 also showed that enhanced biliary manganese excretion occurs in rats 
following repeated manganese inhalation. Dorman et al.
118
 exposed male CD rats to either MnSO4 or Mn3O4 at 
0, 0.03, 0.3, or 3 mg Mn/m
3
 for 6 h/day for 7 days/week (14 exposures). End-of-exposure bile manganese 
concentrations and whole-body 
54
Mn elimination were then determined. Elevated bile manganese 
concentrations and increased whole-body 
54
Mn clearance rates were observed in rats exposed to high 
concentrations (3 mg manganese/m3) of either Mn3O
4
 or MnSO4. These results are consistent with those of 
Cotzias et al.,
186
 who reported dose-dependent manganese elimination in miners exposed to manganese dusts. 
 
Biliary excretion is reduced in neonatal animals and, as we discussed earlier, exposure during this period of 
development may result in increased delivery of manganese to the brain and other tissues. For example, in mice, 
rats, and kittens, there is an almost complete absence of biliary manganese excretion during the neonatal 
period.
190
 However, data in neonatal rats indicate that manganese retention rates decrease around postnatal day 
12 to 16 to approximate rates observed in adult animals. This is indirect evidence that biliary manganese 
excretion may mature during the end of the neonatal period, though the exact time frame across species is 
unknown, or that stores become sufficient and manganese elimination in bile is activated. 
 
Liver disease is a risk factor for increased accumulation of manganese in the CNS, in both animal models and 
hUManS.
145,191,192
 Patients with cholestatic liver disease with biliary atresia (associated with diminished biliary 
excretion of manganese) display hypermanganesemia and T1 -weighted MRI signal hyperintensity in the globus 
pallidus.
193-195
 Analogous MRI findings have been reported in the globus pallidus of cirrhotic patients with 
subclinical hepatic encephalopathy.
196-198
 
 
Liver disease can also alter manganese excretion rates following inhalation exposure. For example, Salehi et 
al.
199
 determined brain manganese accumulation in a rat model of liver disease (end-to-side portacaval 
anastomosis) following inhalation exposure to manganese phosphate (3.05 mg Mn/m
3
 for 8 h, day, 5 days/week 
for 4 consecutive weeks). Salehi et al.
199
 showed that brain manganese concentrations in the cerebellum, frontal 
cortex, and globus pallidus were significantly higher in the manganese-exposed group compared to the control 
group. This study lacked a concurrent manganese-exposed sham surgery control group; thus, this study does not 
clearly demonstrate whether there is the potential for increased manganese brain accumulation in patients with 
compromised liver function. 
 
Manganese exposure can also exacerbate liver dysfunction. For example, an intravenous bolus of bilirubin 
followed by manganese causes cholestasis in rats.
200
 Therefore, liver function is an important consideration in 
the management of individuals with significant manganese exposure. 
 
Pancreatic Excretion 
The pancreas accumulates manganese. Studies conducted in rats have shown that pancreatic excretion of 
manganese accounts for only a small fraction of the absorbed manganese dose.
86
 Kodama et al.
201
 have shown 
that manganese distributed to the pancreas is bound to pro-carboxypeptidase B. Manganese can be excreted in 
pancreatic fluids. Miller et al.
202
 showed that concentrations of manganese in bile and pancreatic juices were 
approximately 0.18 and 0.36 μmol/L, respectively. Ishihara and Matsushiro
203
 showed that mean (± SEM) 
manganese concentrations in pancreatic juices collected from 19 human subjects was 66 ± 13.3 μmol/ml. These 
investigators estimated that daily manganese excretion via the pancreas was approximately 0.1 to 0.13 μmol 
Mn/day (assuming a pancreatic juice flow rate of 1.5 to 2 L/day). Ishihara and Matsushiro
203
 estimated that 
manganese elimination in human urine and bile was approximately 0.018 and 0.18 to 0.36 μmol Mn/day, 
respectively. 
 
Urinary Excretion 
As noted earlier, urinary excretion of manganese is generally low. Mean (± SD) urinary manganese 
concentrations observed in healthy subjects living in northern Italy were 1.02 ± 0.05 pg/L
205
 (Table 3). Paschal 
et al.
206
 reported that a large sample (n = 496) of residents of the United States had a mean urine manganese 
concentration of 0.89 μg/L (25th and 95th percentiles were <0.2 and 3.33 μg Mn/L, respectively) (Table 3). 
Regression analysis demonstrated a gender-based correlation; however, urine manganese concentration was not 
correlated with the age of the subject.
206
 Greger et al.
207
 reported that urinary excretion of manganese by healthy 
male and female subjects was approximately 0.39 and 0.52 μg Mn/g creatinine/day, respectively. 
 
There is conflicting literature as to whether urinary manganese responds to increased dietary or inhalation 
exposure to manganese. Greger et al.
207
 and Davis and Greger
208
 failed to demonstrate a correlation between 
urinary manganese concentration and the dietary intake of manganese in adult male and female volunteers.  
Urinary excretion of manganese following inhalation exposure is also a poor biomarker of exposure.
12
 For 
example, Vitarella and coworkers 
189
 exposed rats by inhalation for 6 h/day for 2 weeks (10 or 14 exposures) to 
manganese phosphate at 0, 0.03, 0.3, or 3 mg Mn/m
3
. Immediately after the end of the inhalation exposure, rats 
were given an intravenous tracer of 
54
Mn, and 24-h fecal and urinary manganese excretion was determined 
during a 16-week postexposure interval. In this study, less than 1% of the administered 
54
Mn tracer could be 
detected in the urine, and urinary manganese excretion was not influenced by inhalation exposure. It has been 
reported that chronically exposed male workers have urine manganese levels that were significantly higher than 
unexposed persons. For example, male foundry workers had a mean manganese level of 5.7 μg/L, compared to 
0.7 μg/L in unexposed controls.
209
 Other studies have reported significantly increased levels of urinary 
manganese in men occupationally exposed to airborne manganese dusts and fumes.
193-195
 For example, Lucchini 
et al.
29
 noted a correlation between manganese urine concentration and cumulative manganese inhalation 
exposure index for workers tested while currently exposed to manganese, but this association was no longer 
present when urine samples were taken > 13 days after cessation of exposure. Mergler et al.,
7
 however, did not 
report a significant difference in urinary manganese levels between the exposed and control groups in their 
occupational study. 
 
Urinary manganese concentrations may be sensitive to manganese depletion. For example, Friedman et al.
16
 
showed that a patient maintained on a low-manganese diet (providing 0.11 mg Mn/day) had markedly reduced 
urinary excretion of manganese following 35 days of dietary manipulation (e.g., decreased from 8.6 μg Mn/day 
to 0.4 μg Mn/day during this time interval). 
 
Excretion Into Milk 
Manganese is also excreted in milk (see Table 1). Manganese concentrations found in human and cow's milk 
can vary dramatically with published ranges of 3-120 and 30-50 μg/L, respectively.
53,55-57
 Manganese levels 
found in rat milk are considerably higher, and they vary during lactation, with the highest concentrations (~330 
μg/ml) found in milk produced during the immediate postnatal period.
210
 Manganese content in human milk 
also varies with lactation.
56-58
 For example, Stastny and coworkers
56
 reported that mean (±SD) human milk 
manganese concentrations in the fourth week of lactation were 6.6 ± 4.7 μg/L and these levels were 
significantly higher than those collected during the 12th week of lactation (3.5 ± 1.4 μg/L) (Table 1). 
 
Elimination in Hair 
Hair can also accumulate high amounts of manganese, and it has been suggested that hair manganese 
concentrations may reflect manganese status.
211
 Bush et al.
212
 reported hair manganese concentrations in 30 
human subjects at 1.44 ± 1.34 μg/g wet tissue. Woolf et al.
33
 have also reported increased hair levels of 
manganese in a child with chronic manganese exposure from drinking water. The hair manganese level in his 
asymptomatic brother was elevated, while blood levels were within the normal range. These studies have 
suggested that hair manganese could serve as a useful biomarker of exposure. Some studies have found a 
correlation between exposure level and manganese concentration in hair.
211
 Several studies have also found 
higher manganese levels in the hair of learning disabled children than in non-disabled children.
211,213
  
Increased manganese levels were also found
214
 in the hair of exposed workers (3.2 times higher than matched 
controls). Other studies, however, have found no correlation between individual hair levels and the severity of 
neurological effects in manganese-exposed persons.
215
 However, interpretation of increased manganese content 
in hair must be viewed with caution since manganese may be more readily found in darker colored hair
216-217 
and dye, bleaching, or other topical treatments may contaminate hair. The suitability of manganese analysis in 
hair for biomonitoring purposes is subject to great background variation and inherent analytical problems.
218
 
 
Clearance of Manganese From the CNS 
Manganese that is delivered to the brain is eliminated over time. Takeda and coworkers
219
 reported a biological 
half-life of manganese in adult rat brain to be on the order of 51 to 74 days. A very similar elimination half-time 
of 53 days has been reported in a macaque monkey given manganese chloride via an implanted subcutaneous 
osmotic minipump.
220
 Newland et al.
220
 also exposed two cynomolgus monkeys to a tracer dose (0.01 to 0.02 μg 
Mn) of 
54
MnCl2 given as an aerosol via an endotracheal tube and then evaluated head and chest 
54
Mn levels by 
gamma spectrometry. They observed that clearance of 
54
Mn from the head was slow with an estimated half-life 
of elimination greater than 220 days. This estimate is likely to be confounded by the relatively slow elimination 
of 
54
Mn from the skull and may not reflect brain elimination rates for this metal. Cotzias and coworkers
186
 
reported brain elimination half-time of 53 days in human beings given intravenous 
54
Mn tracer doses. Dorman 
et al.
93
 reported that neonatal rats given high oral doses of manganese throughout lactation (from PND 1 
through PND 21) had control brain manganese concentrations when assessed at study termination (PND 73). 
This observation suggests an apparent half-life of elimination of manganese from the young adult rat brain to be 
on the order of 50 days or less. 
 
 
 
 
TISSUE MANGANESE CONCENTRATIONS 
Numerous studies are available that describe manganese concentrations in normal and manganese-exposed 
laboratory animals and humans (tissues and biological media) (Tables 1-6). Indeed, the biomarker most used for 
manganese exposure in animal studies is tissue manganese concentrations.
13
 
 
Brain and Tissue Manganese Concentrations in Presumed Normal Humans and in Humans Following 
Manganese Exposure 
Tissue manganese concentrations are occasionally evaluated in human postmortem samples. Bush et al.,
212
 
Yukawa et al.,
221
 and others have reported manganese concentrations in a variety of tissues (Table 2). Tracqui et 
al.
222
 examined brain manganese concentrations in three control subjects, and they reported that globus pallidus, 
putamen, fifth gyrus temporalis, and thalamus manganese concentrations were 0.39 ± 0.05, 0.43 ± 0.11, 0.27 ± 
0.05, and 0.33 ± 0.07 (n = 2) μg/g, respectively. These investigators also reported that a 63- year-old woman 
that was maintained on total parenteral nutrition for 19 months had higher globus pallidus, putamen, and fifth 
gyrus temporalis manganese concentrations (0.95, 1.00, and 0.44 μg/g, respectively) than in the presumed 
normal subjects. 
 
Bonilla and coworkers
223
 determined manganese concentrations in multiple brain regions from eight presumed 
normal people who did not have increased manganese exposure, and showed that the highest concentrations 
were found in the pineal gland and olfactory bulb. Concentrations found in the olfactory bulb (3.36 ± 0.69 μg/g) 
were approximately two- to three-fold higher than those found in the caudate nucleus, putamen, and globus 
pallidus. 
 
Bush et al.
212
 reported brain manganese concentrations in five human subjects in the cerebellum, hippocampus, 
substantia nigra, globus pallidus, and putamen were 1.67 ± 0.50, 1.06 ± 0.68, 1.06 ± 0.33, 1.93 ± 0.89, and 2.08 
± 0.72 μg/g, respectively. Yukawa et al.
221
 reported that manganese concentrations in the cerebellum were 0.52 
± 0.42 μg/g (n = 12). Cerebral and cerebellar manganese concentrations are also available from Japanese 
accident victims, and at the time of autopsy they corresponded to 0.25 ± 0.098 and 0.36 ± 0.11 μg Mn/g wet 
tissue.
224
 However, these values are likely lower than those in the striatum and globus pallidus, both of which 
are known to accumulate more manganese than cerebellum.
225
 
 
A number of studies have examined the relationship between occupational exposure to manganese and brain 
manganese concentrations (as assessed by MRI imaging). A recent cross-sectional study
226
 recently assessed 
healthy workers (48 male and 27 female) at a dry-cell battery factory. Internal exposure was quantified by the 
analysis of manganese in the blood. Chronic exposure was defined as a cumulative index (CBI), including du-
ration of exposure, individual workplace factors, and previously measured concentrations of MnO2 in dust 
samples.
226
 Clinical examinations failed to detect parkinsonisn-like symptoms in any of the tested workers. The 
mean manganese concentration in blood was 12 μg/L (range 3.9-23.3 μg/L) (Table 4). MRI revealed a 
significant positive correlation between manganese levels in blood and manganese concentrations in the brain, 
but no brain atrophy could be detected. An earlier study
227
 also reported an increase in signal intensities on the 
T1-weighted images in asymptomatic manganese-exposed workers compared with manganese nonexposed 
manual workers and nonexposed clerical workers in the same factories. Both studies were not designed to 
determine whether progression of manganism or parkinsonism-like syndromes from manganese exposure 
occurs, and currently this issue remains unresolved. 
 
Additional case-report studies establish that exposure to manganese in welders leads to brain MRI bilateral 
hyperintensity on T1-weighted images in the globus pallidus and other brain regions.
228,229
 A recent study
230
 
also suggests that a parkinsonism-like syndrome in welders is distinguished clinically only by age at onset, 
suggesting that potential exposure to manganese fumes may be a risk factor for Parkinson's disease. However, 
this study did not assess exposure to manganese and a genetic contribution to susceptibility in these exposed 
individuals cannot be excluded. A population-based case-control study to assess occupational exposures to 
metals as risk factors for Parkinson's disease suggests that more than 20 years of exposure to manganese is a 
risk factor for Parkinson's disease.
231
 
 
 
Brain and Other Tissue Manganese Concentrations in Presumed Normal Nonhuman Primates and in 
Nonhuman Primates Following Manganese Exposure 
Brain manganese concentrations have also been reported in experimental cases of manganism in nonhuman 
primates. The most complete information is derived from a study in Indian red-haired monkeys.
185
 After 3 
months of subcutaneous injections to manganese dioxide (MnO2) at three dose levels (0, 2.25, 4.5, and 9 g), 
dose-related increases were noted both in CNS manganese concentrations (20.9, 91.0, 173.7, and 264 μM, in 
striatum; 35.3, 100.7, 241.7, and 334.4 μM, in globus pallidus, respectively), and manganese-associated clinical 
signs. 
 
Ulrich and coworkers
232-234 
evaluated the toxicity of inhaled manganese oxide (MnO2) in male and female 
squirrel monkeys (Saitniri scuireus) and Sprague-Dawley rats. Animals were exposed for approximately 21-22 
h/day, 7 days/week for 9 months, to either filtered air or atmospheres containing 11.6, 112.5, or 1152 μg 
manganese/m
3
 (MMAD = 0.11 μm, sg = 3.07). Elevated kidney manganese concentrations were observed in 
monkeys exposed to either 112.5 or 1152 μg manganese/m
3
. Elevated spleen and whole blood manganese 
concentrations were observed in monkeys exposed to 1152 μg manganese/m
3
. Increased lung manganese 
concentrations were observed in monkeys exposed to either 11.6 or 115 μg manganese/m
3
 (an increase was also 
observed in animals exposed to 1152 μg manganese/m
3
; however, this increase was not statistically significant). 
Brain manganese concentrations were not determined in this study. 
 
Bird and coworkers
235
 exposed female rhesus monkeys (Macaca mullata) for 6 h/day, 5 days/week for 12 
months, to either air or MnO2 at 30 mg Mn/m
3
 (<5 μm particle). Increased putamen and globus pallidus 
manganese concentrations were observed in manganese-exposed monkeys. Mean (±SD) putamen manganese 
concentrations observed in the control and manganese-exposed animals were 1.83 ± 0.20 and 3.15 ± 0.13 μg 
manganese/g wet tissue, respectively. Mean (±SD) globus pallidus manganese concentrations observed in the 
control and manganese-exposed animals were 1.70 ± 0.27 and 3.04 ± 0.36 μg manganese/ g wet tissue, 
respectively. Although caudate and substantia nigra manganese concentrations in manganese-exposed monkeys 
were approximately 134 to 145% of those observed in controls, this increase was not statistically significant 
(most likely due to small sample sizes). Bird and coworkers
235
 also reported that chronic exposure of monkeys 
to MnO2 resulted in a concurrent 34 to 64% decrease in dopamine concentration in the caudate and globus 
pallidus, respectively. 
 
Coulston and Griffin
236
 examined the toxicity of inhaled Mn3O4 in rhesus monkeys and rats. Similar to Ulrich et 
al.,
234
 these investigators also generated their manganese aerosol by burning MMT in a natural gas flame. 
Monkeys were exposed for approximately 23 h/day, 7 days/week for 6 to 15 months, to Mn3O4 at 0.1 mg 
manganese/m
3
. An unexposed group of animals was used as controls. One monkey was killed following 6 
months of manganese exposure and two animals were evaluated after a 15-month exposure period; these groups 
were insufficient to allow for statistical evaluations to be performed. Elevated lung, liver, pancreas, kidney, and 
heart muscle manganese concentrations were observed in the monkeys that were exposed to Mn3O4 for one 
year. Increased pallidum, basal ganglia, cerebellum, and pons manganese concentrations were also observed 
following the 1-yr inhalation exposure. Mean (± SD) basal ganglia manganese concentrations observed in the 
control and manganese-exposed animals were 0.50 ± 0.08 and 1.25 ± 0.128 μg manganese/g wet tissue, 
respectively. 
 
Newland and coworkers
47
 exposed a cynomolgus monkey (Macaca fascicularis) to a MnCl2 aerosol (20 to 40 
mg manganese/m
3
 for 2 h/day, 4 days/week) prior to performing MRI evaluations. Brain MRIs were obtained 
following 3 and 5 months of inhalation exposure. Newland reported that the caudate, putamen, globus pallidus, 
and pituitary gland selectively took up inhaled manganese. 
 
Brain and Other Tissue Manganese Concentrations in Rodents Following Manganese Exposure 
Manganese concentrations in various parts of control rat striatum have been reported to range from 4.4 to 18 
μM.
100,117,237
 In manganese-exposed rats, the levels of manganese in the striatum increase to 23-70 μM . These 
levels must be interpreted with caution in light of differential temporal and dosing regimens. In these studies, 
the manganese was administered in various ways: ( I ) by adding 0, 1, 10, or 20 mg MnCl2/ml to the drinking 
water for 120 days of development; 
100
 (2) by intraperitoneal injection of 1.22 mg manganese (as either MnO2 
or MnCl2)/kg body weight once/week for 4 weeks
117
; (3) or by intrathecal injection of 250 μg MnCl2 into adult 
rats (250 grams of body weight), and sacrifice 6 h later.
227
 As with MRI studies in nonhuman primates,
47
 actual 
manganese levels in the striatum and globus pallidus undoubtedly vary with the time after dosing. 
 
Dorman and colleagues
93,94 
examined the impact of dietary or inhalation exposure. In these studies, postnatal 
day (PND) 10 rats were placed on specially formulated diets that contained 2, 10, or 100 mg manganese/kg diet 
(ppm). The lowest and highest diets were chosen in order to provide the animals with a marginally deficient or 
normal level of manganese. The 10-ppm manganese diet used in these studies met current rodent dietary 
guidelines. After 2 months of dietary manipulation, male rats were exposed by whole-body inhalation for 6 
h/day on 14 consecutive days to MnSO4 or Mn3O4 at concentrations equivalent to 0, 0.03, or 0.3 mg 
manganese/m
3
. Aerosols with similar particle sizes (MMAD of 1.1 to 1.6 μm) were used in these studies. Rats 
exposed to 0.092 mg MnSO4/m
3
 (0.03 mg manganese/m
3
) had elevated lung manganese concentrations when 
compared to air-exposed male rats. Male rats exposed to 0.92 mg MnSO4/m
3
 (0.3 mg manganese/m
3
) developed 
increased striatal, lung, and bile manganese concentrations when compared to air-exposed male rats. Rats given 
a marginally manganese-deficient diet (2 ppm) had decreased cerebellar manganese concentrations compared 
with levels observed in rats given the high-normal manganese diet (100 ppm). Male rats given the marginally 
deficient manganese diet (2 ppm) also developed decreased liver manganese concentrations when compared 
with animals given the 10 ppm manganese diet. Dorman et al.
93
 failed to demonstrate any inhalation-related 
effects on olfactory bulb, cerebellum, liver, testes, serum, or femur manganese concentrations. Likewise, 
olfactory bulb, striatum, lung, bile, testes, and serum manganese concentrations were unaffected by dietary 
treatment despite a 50-fold difference in manganese concentrations used in this study. 
 
Manganese Speciation (Divalent vs. Trivalent Forms) 
In nature, manganese can exist in all oxidation states from 2+ to 7+, with divalent manganese being the most 
relevant to biological conditions. The extent of the neurotoxicity of manganese appears to be determined by its 
oxidation state. Manganese is putatively transported into cells in its divalent state and oxidized intracellularly, 
via reaction with the super-oxide anion to the trivalent state.
238
 Manganese in the trivalent state has been linked 
to cytotoxicity, particularly to dopaminergic cells and other catecholamines in the brain.
238
 Furthermore, in the 
mitochondria, it has been demonstrated that manganese will inhibit complex I thereby leading to altered 
oxidative phosphorylation.
183,184,238
 Trivalent manganese has a stronger affinity for complex I than divalent 
manganese, but divalent manganese is the most predominant species in vivo. Nevertheless, manganese in any 
oxidation state will likely spontaneously give rise to some trivalent manganese. HaMai et al.
239
 demonstrated 
that even at trace amounts, trivalent manganese can cause formation of reactive oxygen species. They also 
showed evidence that divalent manganese fails to induce oxidative effects. While its oxidation state will 
determine manganese transport and kinetics (e.g., transferrin binds to trivalent manganese exclusively
90,91, 119
), 
there are no readily available methods for determining the valence of manganese within the body. 
 
BIOMARKERS OF EXPOSURE 
Blood Manganese Concentrations 
Whole blood, serum, and plasma manganese are the readily available biomarkers of manganese status in 
humans. An ad-vantage of determining whole-blood manganese concentrations, instead of plasma or serum 
concentration, is that even slight sample hemolysis can result in artificial increases in serum or plasma 
manganese concentrations. This effect is due to red blood cell manganese concentrations being 10- to 15-fold 
higher than that of serum or plasma.
14,240,241 
Riikgauer et al.
242
 reported that adult humans aged 22 to 75 years 
had mean (± SD) plasma manganese concentrations of 0.79 ± 0.3 μg manganese/L (14.3 ± 5.7 nmol/L) (Table 
3). No correlation was observed between plasma manganese concentration and the age or gender of the adult 
subject. In general, the available data (Table 3) suggest an apparent age-related decrease in manganese blood 
concentrations. The implications of this observation for determining age-related levels of manganese, and, by 
implication, age-related safe exposure levels are unknown. 
 
Children (1 month to 18 years of age) had mean (±SD) serum manganese concentrations of 1.4 ± 0.63 μg 
manganese/L (25.5 ± 11.4 nmol/L).
242
 A negative correlation between serum manganese concentration and the 
age of the child was observed. For example, mean (±SD) serum manganese concentrations of 2.1 ± 0.81 μg 
manganese/L and 0.96 ± 0.31 μg manganese/L were observed in infants aged 0 to 6 months (n = 13) and 
children aged 14 to 18 years of age (n = 17), respectively (Table 5). Neonates also have blood manganese 
concentrations that are threefold higher than in adults (Table 5), which may be indicative of increased 
absorption, reduced excretion, or higher requirement for manganese stores. Whole-blood manganese 
concentrations from normal children are the highest in neonates, and decrease with age reaching a stable level at 
1 year of age (Table 5).
243
 
 
Diaz et al.
244
 also reported serum manganese concentrations in a representative sample of citizens living in the 
Canary Islands (n = 368 individuals ranging from 6 to 75 years of age). Their results are consistent with those 
re-ported by Riikgauer et al.
242
 (Table 3) in that no correlation was observed between serum manganese 
concentration and the gender of the subject and children had higher serum manganese concentrations when 
compared to adults (Tables 3 and 5). These investigators observed a mean (±SD) serum manganese 
concentration of 1.06 ± 0.62 μg manganese/L (range from 0.19 to 3.33 μg manganese/L). Whole blood 
manganese concentrations are sensitive to developmental life stage (Tables 3 and 5). Pregnant women and 
infants often have elevated blood manganese concentrations (Table 6).
245
 Studies examining whole-blood 
concentrations of manganese during pregnancy show an increase throughout gestation (Table 6), and iron 
supplementation of pregnant women with normal iron status does not significantly change blood manganese 
concentrations.
246 
 
Several studies have shown that serum or plasma manganese concentrations respond to dietary intake. For 
example, Davis and Greger
208
 showed that women consuming 1.7 mg manganese/ day had lower serum 
manganese concentrations than did women ingesting 15 mg manganese/day. A statistically significant positive 
correlation has been observed between serum manganese concentrations of human-milk-fed infants and both the 
manganese concentration of the consumed milk and the daily intake of manganese.
56
 
 
 
Freeland-Graves and Turnlund
247
 showed that plasma manganese concentrations were reduced as human 
subjects consumed diets intended to deplete body stores of manganese. These investigators also showed that 
plasma manganese concentrations increased when the diets were supplemented with manganese. Serum and 
plasma manganese concentrations can be insensitive to large variations in dietary manganese intake and are not 
predictive of dietary intake. For example, Stastny et al.
56
 showed that mean (±SD) serum manganese 
concentrations observed in infants fed human milk were identical to those seen in formula-fed infants (4.4 ± 1.8 
vs. 4.7 ± 1.6 μg manganese/L) despite a >400-fold higher daily manganese intake in the formula-fed infants 
(0.42 vs. 183 μg manganese/kg). 
 
Whole blood, serum, and plasma manganese concentrations have also been evaluated in individuals exposed to 
air-borne manganese, most commonly in an occupational setting (Table 4). The strength of the observed 
correlation between blood manganese concentrations and manganese exposure concentrations often depends on 
the magnitude and the duration of the exposure. In some studies, whole-blood manganese concentrations 
positively correlate with exposure to manganese (Table 4). In other cases, blood manganese concentrations in 
exposed workers remain in the normal adult range (4-14 μg manganese/L) and urine and hair manganese 
concentrations do not differ between exposed and non-exposed workers (Table 4). The poor correlation between 
air and blood manganese concentration may be related to the extremely short (~5 min) half-life of manganese in 
the blood following acute inhalation exposure.
248 
 
Lymphocytic Manganese Superoxide Dismutase Activity 
Another potential biomarker of early biochemical effect of manganese (not necessarily exposure) is the 
determination of lymphocytic manganese-superoxide dismutase (MnSOD) activity. Davis and Greger
208
 
demonstrated that lymphocytic MnSOD activity was elevated in 4 women supplemented with 15 mg 
manganese/day for more than 3 months. MnSOD is also an imperfect biomarker since it may also be affected by 
ethanol exposure,
249
 nonheme iron,
86 
strenuous exercise,
250
 and diets rich in polyunsaturated fatty acids.
251
 
 
 
 
Arginase Activity 
Arginase activity is also sensitive to manganese tissue concentrations
252,253 
and may hold some future promise 
as a biomarker of exposure for manganese.
13
 
 
Magnetic Resonance Imaging (MRI) 
Most tissue concentrations are relatively inaccessible in humans without the use of biopsy procedures and thus 
their usefulness as a biomarker is quite limited. One procedure that may hold a great deal of promise as a 
biomarker of exposure involves the use of magnetic resonance imaging (MRI) techniques. MRI is based on the 
absorption and emission of energy in the radio frequency range of the electromagnetic spectrum. Manganese is 
paramagnetic. Paramagnetic substances shorten the T1-weighted value obtained on MRI. MRI procedures have 
revealed that humans accumulate manganese within discrete brain structures including the striatum, globus 
pallidus, and substantia nigra.
5,46,77,254
 These hyperintensities are bilateral, symmetrical, and visible in T 1-
weighted magnetic resonance imaging of different manganese overload conditions. There have been numerous 
reports of clinical studies on relations or correlations among blood manganese concentrations, and intensity on 
T1-weighted images (MRI intensity). 
 
For example, Takagi et al.
77
 have shown a high degree of correlation between the T1-weighted intensity of the 
MRI image obtained from the globus pallidus and whole-blood manganese concentrations in human subjects (n 
= 12; 17 to 62 years of age at the time of entry on the study) that were given total parenteral solutions providing 
either 0, I , 2, or 20 μmol manganese/day for 4.6 to 19.5 months. Both manganese blood concentration and 
Pallidal Index (PI)* represent highly variable measurements (the former not representing a good indicator of 
chronic manganese exposure) and with time may be developed as an accurate biomarker of manganese 
exposure.
255
 However, although patients with different T1-weighted intensities are recognized clinically, there 
have been few efforts made to determine whether image intensity directly correlates with brain manganese 
concentrations. 
 
Gallez and coworkers
256
 recently reported a positive correlation between NMR proton T1 relaxation times 
(obtained using a 4.7 Tesla imager) and brain manganese concentrations as determined by atomic absorption 
spectrometry in manganese-exposed rats. It is likely that a similar approach could also be applied to human 
clinical imaging studies; however; there is in-sufficient evidence to suggest that data from Gallez et al.
256 
could 
be used directly to estimate brain manganese concentrations in exposed humans. 
 
ADDITIONAL FACTORS THAT CAN INFLUENCE MANGANESE TISSUE CONCENTRATIONS 
Manganese Deficiency 
Dietary intake of manganese is known to influence the amount of manganese absorbed from the gastrointestinal 
tract and the amount of manganese eliminated in the bile. When dietary manganese levels are high, adaptive 
changes often include reduced gastrointestinal absorption of manganese, enhanced manganese liver metabolism, 
and increased biliary and pancreatic excretion of manganese.
18,86,92-97
 
 
Few investigators have examined whether dietary manganese levels can influence the pharmacokinetics of 
inhaled manganese. Moore and coworkers
257
 evaluated tissue manganese concentrations in rats fed either a 5- or 
42.2-ppm manganese diet and exposed subchronically (8 h/day for 56 consecutive days) to irradiated exhaust 
from an automobile engine using gasoline containing MMT. These authors reported that brain, kidney, and liver 
manganese concentrations were lower in air-exposed control animals fed a 5-ppm manganese diet compared to 
animals fed the 42.2-ppm manganese diet. Animals fed either the 5- or 42.2-ppm manganese diet and exposed 
to irradiated exhaust (containing approximately 117 μg Mn/m
3
) developed a 45 or 84% increase in total brain 
manganese concentrations, respectively, compared with air-exposed controls (i.e., no manganese in air). 
However, the results of this study were not analyzed in such a manner as to determine whether diet and 
inhalation inter-active effects occurred. Although not determined directly during this study, the most likely form 
of manganese in the engine exhaust was the tetroxide, Mn304, since a catalytic converter was not used in the 
generation system.
258
 
 
Recent studies by Dorman et al.
93,94
 determined the influence of manganese body burden on the 
pharmacokinetics of inhaled manganese sulfate (MnSO4) and manganese tetraoxide (Mn3O4) in neonatal rats 
(postnatal day 10; PND 10) reared on either a low (2 ppm), sufficient (10 ppm), or high (100 ppm) manganese 
diet. Once tissue manganese concentrations stabilized (i.e., after 2 months on the special diets), male rats were 
exposed by whole-body inhalation for 6 h/day on 14 consecutive days to MnSO4 or Mn3O4 at concentrations 
equivalent to 0, 0.03, or 0.3 mg manganese/m3. Dorman and coworkers then evaluated a variety of tissues for 
their manganese content and determined the rate of manganese elimination by whole-body gamma spectrometry 
following intravenous administration of a 
54
Mn tracer. 
 
As expected, Dorman and coworkers
93,94 
found that the feeding of a marginally deficient diet containing only 2 
ppm manganese was associated with a number of effects, including reduced body weight gain, decreased liver 
manganese concentrations, and reduced whole-body manganese clearance rates. They also showed that biliary 
excretion of manganese was influenced by oral manganese intake. Rats kept on the marginally manganese-
deficient diet had decreased biliary manganese concentrations and slower elimination of the 
54
Mn tracer when 
compared with rats given manganese-sufficient diets. Male rats exposed to 0.3 mg manganese/m
3
 developed 
increased manganese concentrations in some tissues; however, this study did not demonstrate significant diet 
and inhalation interactions on brain manganese concentrations. Despite being in a relatively manganese-
deficient state, rats given the 2-ppm manganese diet and exposed to MnSO4 or Mn3O4 increased their rate of 
manganese excretion when compared to their respective air-exposed control groups. This observation suggests 
that, at least initially, under these experimental conditions animals will not retain inhaled manganese to 
compensate for relative nutritional deficiencies in this essential metal. 
 
 
Lifestage 
The pharmacokinetics of manganese during critical phases of development has been most thoroughly examined 
using the oral route of exposure. As with other xenobiotics, manganese exposure to the developing nervous 
system is a function of the dose administered to the dam and the pharmacokinetics of the com-pound in the 
maternal, placental, and embryo/fetal (or neonatal) circulations. 
 
Concern exists that elderly individuals may be another sensitive subpopulation at increased risk for the onset of 
neurologic disorders and that elevated exposures to manganese in the pre-parkinsonism state might be 
associated with an increased incidence of Parkinson's disease. In a study where a pre-parkinsonian state was 
induced by a unilateral intrastriatal injection of 6-hydroxydopamine (6-OHDA, a dopaminergic neurotoxin), 
followed 4 weeks later by exposure to manganese (4.8 mg manganese/kg x 3 intraperitoneal injections/week, 
for 5 weeks), rat brain manganese levels were 3.4-fold increased in over controls.
259
 Notably, manganese 
exposure in the presence of a pre-parkinsonian state (but not in its absence) also significantly exacerbated some 
neurobehavioral effects of manganese suggesting that manganese exposure may increase the risk of 
neurological impairment in elderly populations with a pre-parkinsonian state. 
 
Dorman et al.
260
 recently completed a series of experiments to evaluate whether manganese pharmacokinetics is 
altered in aged animals. Dorman et al.
260
 determined the pharmacokinetics of manganese phosphate and 
manganese sulfate (MnSO4) in young adult and senescent (> 16-month old) male CD rats following subchronic 
inhalation exposure (6 h/day, 5 days/week, for 13 weeks). Nominal MnSO4 exposure concentrations of 0, 0.01, 
0.1, and 0.5 mg manganese/m
3
 and a single manganese phosphate exposure concentration of 0.1 mg 
manganese/m
3
 were used. Rats were evaluated at the end of the 90-day exposure and at 45 days postexposure. 
An overall age-related main treatment effect was observed on some tissue manganese concentrations. Young 
male rats had significantly higher olfactory bulb, blood, femur, and pancreas manganese concentrations when 
compared to senescent male rats. Increased olfactory bulb manganese concentrations in young rats are most 
likely related to a portal-of-entry effect arising from a higher pulmonary ventilation rate in young animals. 
Young male rats also had significantly lower testes manganese concentrations when compared to old males. The 
aging rat testes have been shown to accumulate other metals. One possible explanation for increased manganese 
delivery to the testes of senescent animals is decreased integrity of the seminiferous epithelium and the blood—
testis barrier that occurs in aged rats.
261
 The results of this study do not suggest that the aged rat nervous system 
accumulates more manganese than in young animals. 
 
Iron Deficiency 
Worldwide, the prevalence of iron deficiency anemia (IDA) in infants and children is estimated to be at 
approximately 25%.
262
 A report from the World Health Organization estimates that 46% of the world's 5- to 14-
year-old children and 48% of the world's pregnant women are anemic.
263,264
 A majority of these cases of anemia 
are due to iron deficiency. According to data from the third National Health and Nutrition Examination Survey 
(NHANES III, I 988-1994),
265
 the prevalence of IDA in U.S. children between 1 and 2 years of age is 3% and 
the prevalence of iron deficiency without anemia is 9%. This prevalence corresponds to ~240,000 and 700,000 
infants, respectively. Further-more, the prevalence of iron deficiency among women of child-bearing age (20-49 
years of age) has been reported to range from 8 to 20%,
266
 suggesting that infants may be at risk for marginal to 
low iron status not only as a result of postnatal factors, but also as a result of limited prenatal iron sources. 
 
The neurobiological consequences of iron deficiency include alterations in behavior, cognition, and 
neurotransmitter metabolism.
176,267,268
 Offspring of marginal iron dams demonstrate lower grip strength, 
attenuated startle responsiveness, and altered performance in the Morris water maze. These differences in 
performance were found in association with lower brain iron concentrations. Notably, iron deficiency is also 
associated with decreased dopamine D2 receptors in striatum,
269,270
 increased extracellular dopamine 
concentrations,
271-273
 decreased dopamine transporter and dopamine receptor functioning,
274,275
 thus sharing a 
number of commonalities with manganese-induced neurotoxicity.
276
 These commonalities raise the possibility 
that the neurological seguelae of iron deficiency are mediated, or, at least potentiated, by increased CNS 
manganese concentrations. Additional research will be required to determine whether this interaction indeed 
occurs. 
 
DMT-1 mRNA levels are significantly increased in patients with iron deficiency and hereditary 
hemochromatosis, whereas they are unchanged in patients with secondary iron overload.
277
 Alterations in DMT-
1 mRNA levels are paralleled by comparable changes in the duodenal expression of these proteins. In patients 
with normal iron status or iron deficiency, significant negative correlations between DMT-1 mRNA and serum 
iron level parameters have been noted. Manganese levels in these patients have not been determined, and no 
data are currently available on the potential that increased DMT-1 mRNA expression translates to increased 
plasma or brain manganese load. Maternal iron deficiency during pregnancy induces anemia in the developing 
fetus; however, the severity tends to be less than in the mother as a result of an increased efficiency of iron 
flux.
132
 
 
In a recent study
176
 weanling rats were fed one of three semipurified diets: control, iron deficient (ID), or iron 
deficient/manganese fortified (IDMn+). Plasma transferrin (significant increase) and iron concentrations 
(significant decrease) were characteristic of severe anemia in the ID and IDMn+ groups.
176
 Seven brain regions 
(caudate putamen, globus pallidus, thalamus, hippocampus, substantia nigra, cerebellum, and cortex) were 
analyzed for manganese concentration. Both ID and IDMn+ diets caused significant increases in manganese 
concentration across brain regions compared to control diets; however, increased dietary manganese (IDMn+) 
did not increase brain manganese concentration beyond the level associated with ID, except in the 
hippocampus. 
 
Vegetarian Diets 
Increasing numbers of young people are adopting a vegetarian lifestyle. The effect of vegetarian diets on iron 
status is controversial. In a recent study, Pongstaporn et al.
278
 reported on hematological parameters and serum 
ferritin in 179 vegetarians and 58 control (with no known disease) subjects. It was found that hemoglobin, 
hematocrit, and serum ferritin in vegetarians were significantly lower than in control subjects. There were 34 
cases of iron-deficiency in 179 vegetarians (19%), which can be classified to iron depletion (4 cases), iron-
deficient erythropoiesis (12 cases) and iron-deficiency anemia (18 cases). Conversely, Hunt et al.
279
 suggested 
that iron status in women consuming controlled lacto-ovovegetarian diets for 8 weeks is unaltered compared to 
women on a nonvegetarian diet. The physiologic adaptation was reflected by an increase in the efficiency of 
iron absorption and insensitivity of blood iron indexes, including serum ferritin, despite 70% lower nonheme 
iron absorption from a lacto-ovovegetarian diet. At the time of this writing, the relationship between vegetarian 
lifestyle, adaptation to increased iron absorption (potentially via the up regulation of DMT-1), and manganese 
uptake from a diet likely to exceed normal manganese intake (given the higher content of manganese in 
vegetarian food of plant origin) is undetermined. Thus the combination of iron deficiency and a diet skewed to 
higher than usual manganese levels (vegetables, cereals, etc.) in vegetarians should be considered for its 
potential adverse interaction (i.e., inverse diet-manganese interaction). 
 
CONCLUSIONS 
Much is known about the dosimetry of manganese; however, this information has been incompletely integrated 
into rigorous quantitative risk assessments for this metal. Future risk assessments would benefit from the 
development of physiologically based pharmacokinetic (PBPK) models for manganese. The power of 
biologically based dosimetry models rests in their ability to estimate the amount of the active form of a 
chemical at its target site within the body over time, given virtually any exposure paradigm. Risk assessments 
will need to consider life stage since this is an important determinant of manganese pharmacokinetics and 
response. Comprehensive risk assessments for manganese should also consider oxidation states of manganese in 
the blood, uptake rates of protein-bound forms of manganese by the liver, neuronal transfer rates within the 
brain, olfactory transport to brain manganese delivery, and mechanisms of manganese-induced 
neurotoxicity.
12,166
 
 
 
Note: 
* PI represents the ratio of globus pallidus to subcortical frontal white-matter signal intensity in T1-weighted 
MRI planes multiplied by 100. 
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